XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.33%26.23B | 14.31%6.41B | 4.62%6.55B | 0.62%6.32B | -3.92%6.95B | 1.45%25.38B | -4.47%5.6B | 5.16%6.26B | -6.31%6.29B | 11.41%7.24B |
Net interest income | 1.79%12.94B | ---- | 1.88%3.31B | -6.54%3.06B | 0.62%3.07B | 20.21%12.71B | ---- | 5.83%3.25B | 35.01%3.27B | 30.41%3.05B |
-Net interest income | 9.27%38.33B | ---- | 1.88%3.31B | 23.78%15.57B | 0.62%3.07B | 83.68%35.08B | ---- | 5.83%3.25B | 162.45%12.58B | 30.41%3.05B |
-Total interest expense | 13.52%25.39B | ---- | ---- | ---- | ---- | 162.39%22.37B | ---- | ---- | ---- | ---- |
Non interest income | 4.88%13.29B | ---- | 7.57%3.24B | 8.39%3.27B | -7.24%3.88B | -12.28%12.68B | ---- | 4.44%3.01B | -29.65%3.02B | 0.70%4.18B |
-Fees and commissions | 2.42%4.52B | ---- | 7.57%3.24B | 14.19%-1.6B | -7.24%3.88B | -3.20%4.42B | ---- | 4.44%3.01B | -1.53%-1.86B | 0.70%4.18B |
-Dividend income | --3M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Credit losses provision | ||||||||||
Non interest expense | ||||||||||
Selling and administrative expenses | 6.46%2.77B | ---- | ---- | ---- | ---- | 14.63%2.6B | ---- | ---- | ---- | ---- |
-General and administrative expense | 5.16%2.12B | ---- | ---- | ---- | ---- | 13.95%2.02B | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 10.94%649M | ---- | ---- | ---- | ---- | 17.00%585M | ---- | ---- | ---- | ---- |
-Depreciation and amortization | -4.71%1.7B | ---- | ---- | ---- | ---- | 3.54%1.78B | ---- | ---- | ---- | ---- |
Income from associates and other participating interests | 511.11%37M | -250.00%-9M | ||||||||
Special income (charges) | 77.66%-424M | 82.58%-325M | -35M | -30.70%-149M | -5,800.00%-57M | -9.90%-1.9B | -792.82%-1.87B | 0 | 91.49%-114M | 100.19%1M |
Less:Restructuring and mergern&acquisition | -124.78%-112M | ---- | ---- | ---- | ---- | 6,557.14%452M | ---- | ---- | ---- | ---- |
Less:Impairment of capital assets | -90.63%34M | ---- | ---- | ---- | ---- | 476.19%363M | ---- | ---- | ---- | ---- |
Less:Other special charges | -53.65%502M | -61.66%403M | --35M | -78.79%7M | 5,800.00%57M | -35.19%1.08B | 586.93%1.05B | ---- | -97.53%33M | -100.19%-1M |
Other non-operating income (expenses) | 133.33%21M | 340.00%12M | 1,000.00%9M | 50.00%-5M | ||||||
Income before tax | 23.65%8.11B | 1,410.00%1.66B | 18.41%2.23B | -1.32%1.94B | -12.36%2.28B | -6.49%6.56B | -91.60%110M | -4.27%1.89B | 31.02%1.96B | 16.29%2.6B |
Income tax | 41.98%1.75B | 2,047.83%448M | 20.12%412M | 20.96%427M | -17.11%465M | 18.77%1.23B | 30.30%-23M | 37.75%343M | 68.90%353M | -8.63%561M |
Earnings from equity interest net of tax | ||||||||||
Net income | 19.41%6.36B | 812.03%1.21B | 18.03%1.82B | -6.21%1.51B | -11.05%1.81B | -10.88%5.32B | -90.10%133M | -10.35%1.54B | 24.88%1.61B | 25.74%2.04B |
Net Income continuous operations | 19.41%6.36B | 812.03%1.21B | 18.03%1.82B | -6.21%1.51B | -11.05%1.81B | -10.88%5.32B | -90.10%133M | -10.35%1.54B | 24.88%1.61B | 25.74%2.04B |
Minority interest income | -23.44%49M | -20.00%20M | -66.67%3M | 4.55%23M | -62.50%3M | 42.22%64M | 13.64%25M | 350.00%9M | 10.00%22M | 700.00%8M |
Net income attributable to the parent company | 19.93%6.31B | 1,004.63%1.19B | 18.53%1.82B | -6.36%1.49B | -10.84%1.81B | -11.29%5.26B | -91.82%108M | -10.77%1.53B | 25.12%1.59B | 25.32%2.03B |
Preferred stock dividends | ||||||||||
Other preferred stock dividend | 0.61%991M | 4.11%228M | -2.32%253M | -3.83%251M | 5.28%259M | 8.84%985M | -23.16%219M | 25.73%259M | 31.16%261M | 14.42%246M |
Net income attributable to common stockholders | 24.38%5.32B | 969.37%965M | 22.76%1.56B | -6.85%1.24B | -13.07%1.55B | -14.91%4.27B | -110.71%-111M | -15.74%1.27B | 24.00%1.33B | 26.99%1.78B |
Basic earnings per share | 29.96%1.44 | 1,440.00%0.268 | 28.92%0.428 | -3.49%0.332 | -8.85%0.412 | -10.06%1.108 | -107.58%-0.02 | -11.70%0.332 | 34.38%0.344 | 34.52%0.452 |
Diluted earnings per share | 29.37%1.392 | 1,013.58%0.268 | 28.92%0.428 | -2.78%0.332 | -8.85%0.412 | -9.73%1.076 | -111.23%-0.0293 | -11.70%0.332 | 33.39%0.3415 | 34.52%0.452 |
Dividend per share | -9.43%0.281 | 0 | 7.22%0.1136 | 0 | -18.06%0.1675 | 26.24%0.3103 | 0 | 18.77%0.1059 | 0 | 30.50%0.2044 |
Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |